Migraine
Conditions
Brief summary
A prospective, double-blind, randomized, sham-controlled, multicentre investigation.
Detailed description
The study period will begin with a four week run-in period, during which there is no investigational treatment. The purpose of the run-in period will be observation for baseline comparison. The run-in period will be, followed by a 12 week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment. The randomized period will be followed by a 24 week open label period, where the subjects in the sham treatment group will switch in treatment assignment and receive a gammaCore®-R and the gammaCore®-R will continue to receive an active treatment.
Interventions
DEVICEgammaCore®-R
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
DEVICEgammaCore®-R Sham
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
Sponsors
ElectroCore INC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Is between the ages of 18 and 75 years. 2. Has been previously diagnosed with migraine (with or without aura) in accordance with the International Classification of Headache Disorders (ICHD)-3 Beta Classification criteria. 3. Experience between 5 and 12 migraine days per month (over the last 4 months) with at least 2 of the migraines lasting more than 4 hours. 4. Has age of onset of migraine less than 50 years old. 5. Agrees not to use any migraine prevention treatments (including Botox injections) and/or medications (exclusive of medications taken for acute relief of migraine symptoms). 6. Agrees to refrain from initiating or changing the type, dosage or frequency of any prophylactic medications for indications other than migraine that in the opinion of the clinician may interfere with the study objectives (e.g. antidepressant, anti convulsant, beta blockers, etc.). 7. Agrees to use the gammaCore®-R device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires. 8. Is able to provide written Informed Consent.
Exclusion criteria
1. Has a concomitant medical condition that will require oral or injectable steroids during the study. 2. Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma. 3. Has a structural abnormality at the gammaCore®-R treatment site (e.g lymphadenopathy previous surgery or abnormal anatomy). 4. Has pain at the gammaCore®-R treatment site (e.g.dysesthesia, neuralgia and/or cervicalgia). 5. Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or facial disorder) that in the opinion of the investigator may confound the study assessments 6. Has know or suspected severe cardiac disease(e.g. symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF)). 7. Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery). 8. Has an abnormal baseline Electrocardiogram (ECG) e.g. second and third degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction). 9. Has had a cervical vagotomy. 10. Has uncontrolled high blood pressure (systolic \>160 diastolic \> 100 after 3 repeated measurements within 24 hours). 11. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator). 12. Has been implanted with metal cervical spine hardware or has a metallic implant near the gammaCore®-R stimulation site. 13. Has a known history of suspicion of secondary headache. 14. Has a history of syncope (within the last five years). 15. Has a history of seizures (within the last five years). 16. Has a known or suspicion of substance abuse or addiction (within the last 5 years). 17. Is using marijuana (including medical marijuana) for any indications, more than twice a month. 18. Currently takes simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) greater than 15 days per month or triptans, ergots or combined analgesics greater than 10 days per month for headaches or other body pain. 19. Currently takes prescription opioids greater than 2 days per month for headaches or body pain. 20. Has taken medications for migraine prophylaxis in the previous 30 days. 21. Has previous diagnosis of medication overuse headache (MoH) , which has reverted to episodic migraine within the last 6 months. 22. Meets the ICHD-3 Beta Classification criteria for chronic migraine (\> 15 headache days per month). 23. Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine . 24. Has had surgery for migraine prevention. 25. Has undergone nerve block (occipital or other) in the head or neck within the last 2 months. 26. Has received Botox injections within the last 6 months. 27. Is pregnant or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use and accepted form of birth control. 28. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days. 29. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner). 30. Is a relative of or an employee of the investigator or the clinical study site. 31. Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the clinician may interfere with the study. 32. Has previously used the gammaCore® device.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Number of Migraine Days | last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period. | Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Number of Headache Days | The last four weeks in the randomization period compared to the four week run-in period. | The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period. |
| Change in Number of Acute Medication Days | The last four weeks in the randomization period compared to the four week run-in period. | The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period |
| Change in Headache Disability Using Headache Impact Test-6 | From four week run-in period to last four weeks in the randomization period | Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact. |
| Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | 3 months - end of run-in period to end of randomized period | Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded: 0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability |
| Number of Participants With 50% Responder Rate | The last four weeks in the randomization period compared to the four week run-in period. | The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period. |
| Change in Migraine Days in the Open Label Period (Adjusted ANCOVA) | The 6 month open-label period compared to the four week run-in period | Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period. |
| Number of Participants With Adverse Events | up to Week 36 | Adverse Effects were collected for all subjects for the duration of the study. |
| Change in Headache Days in the Open Label Period | The 6 month open-label period compared to the four week run-in period | The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period |
| Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | From four week run-in period to last four weeks in the randomization period | The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5). Minimum score is 5 (no problems) and maximum score is 25 (extreme problems) An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health |
Countries
Belgium, Denmark, Germany, Greece, Netherlands, Norway, Spain, United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| gammaCore®-R Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side). | 165 |
| gammaCore®-R Sham Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side). | 167 |
| Total | 332 |
Baseline characteristics
| Characteristic | gammaCore®-R | gammaCore®-R Sham | Total |
|---|---|---|---|
| Age, Continuous | 43.5 years STANDARD_DEVIATION 11.11 | 41.4 years STANDARD_DEVIATION 12.26 | 42.4 years STANDARD_DEVIATION 11.73 |
| Race/Ethnicity, Customized Race Asian | 1 Participants | 3 Participants | 4 Participants |
| Race/Ethnicity, Customized Race Black | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Caucasian | 160 Participants | 154 Participants | 314 Participants |
| Race/Ethnicity, Customized Race Other | 4 Participants | 8 Participants | 12 Participants |
| Region of Enrollment Belgium | 11 participants | 11 participants | 22 participants |
| Region of Enrollment Denmark | 17 participants | 16 participants | 33 participants |
| Region of Enrollment Germany | 36 participants | 32 participants | 68 participants |
| Region of Enrollment Greece | 15 participants | 16 participants | 31 participants |
| Region of Enrollment Netherlands | 15 participants | 16 participants | 31 participants |
| Region of Enrollment Norway | 6 participants | 6 participants | 12 participants |
| Region of Enrollment Spain | 22 participants | 22 participants | 44 participants |
| Region of Enrollment United Kingdom | 43 participants | 48 participants | 91 participants |
| Sex: Female, Male Female | 142 Participants | 138 Participants | 280 Participants |
| Sex: Female, Male Male | 23 Participants | 29 Participants | 52 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 169 | 0 / 172 | 0 / 136 | 0 / 277 |
| other Total, other adverse events | 74 / 169 | 91 / 172 | 13 / 136 | 118 / 277 |
| serious Total, serious adverse events | 2 / 169 | 1 / 172 | 0 / 136 | 2 / 277 |
Outcome results
Primary
Change in the Number of Migraine Days
Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.
Time frame: last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.
Population: Randomized population, Intention to Treat (ITT)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| gammaCore®-R | Change in the Number of Migraine Days | -1.98 Days | Standard Deviation 3.031 |
| gammaCore®-R Sham | Change in the Number of Migraine Days | -1.53 Days | Standard Deviation 3.09 |
Secondary
Change in Headache Days in the Open Label Period
The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period
Time frame: The 6 month open-label period compared to the four week run-in period
Population: Randomized population (Intent to treat)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| gammaCore®-R | Change in Headache Days in the Open Label Period | -0.55 Days |
| gammaCore®-R Sham | Change in Headache Days in the Open Label Period | -0.51 Days |
Secondary
Change in Headache Disability Using Headache Impact Test-6
Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact.
Time frame: From four week run-in period to last four weeks in the randomization period
Population: Randomized population, Intention to Treat (ITT) In the active group 23 subjects had missing data, in the sham group 32 subjects had missing data at the end of the randomized period
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| gammaCore®-R | Change in Headache Disability Using Headache Impact Test-6 | HIT-6 score Run-in perio | 63.442 units on a scale |
| gammaCore®-R | Change in Headache Disability Using Headache Impact Test-6 | HIT-6 score end of Randomized period | 60.234 units on a scale |
| gammaCore®-R Sham | Change in Headache Disability Using Headache Impact Test-6 | HIT-6 score Run-in perio | 64.263 units on a scale |
| gammaCore®-R Sham | Change in Headache Disability Using Headache Impact Test-6 | HIT-6 score end of Randomized period | 60.992 units on a scale |
Secondary
Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)
Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period.
Time frame: The 6 month open-label period compared to the four week run-in period
Population: Randomized population (Intent to treat)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| gammaCore®-R | Change in Migraine Days in the Open Label Period (Adjusted ANCOVA) | Migraine days run in period | 7.94 Days |
| gammaCore®-R | Change in Migraine Days in the Open Label Period (Adjusted ANCOVA) | Migraine days open label period | 5.75 Days |
| gammaCore®-R Sham | Change in Migraine Days in the Open Label Period (Adjusted ANCOVA) | Migraine days run in period | 7.9 Days |
| gammaCore®-R Sham | Change in Migraine Days in the Open Label Period (Adjusted ANCOVA) | Migraine days open label period | 5.7 Days |
Secondary
Change in Number of Acute Medication Days
The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period
Time frame: The last four weeks in the randomization period compared to the four week run-in period.
Population: Randomized population, Intention to Treat (ITT)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| gammaCore®-R | Change in Number of Acute Medication Days | -1.65 acute medication days | Standard Deviation 3.31 |
| gammaCore®-R Sham | Change in Number of Acute Medication Days | -1.02 acute medication days | Standard Deviation 3.31 |
Secondary
Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)
The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5). Minimum score is 5 (no problems) and maximum score is 25 (extreme problems) An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health
Time frame: From four week run-in period to last four weeks in the randomization period
Population: Randomized population, Intention to Treat (ITT) In the active group 24 subjects had missing data, in the sham group 35 subjects had missing data at the end of the randomized period
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Mobility run-in period | 1.10 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Mobility randomized period | 1.09 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Selfcare run-in period | 1.02 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Selfcare randomized period | 1.02 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Usual activities run-in period | 1.27 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Usual activities randomized period | 1.24 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Pain/discomfort run-in period | 1.56 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Pain/discomfort randomized period | 1.50 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Anxiety/depression run-in period | 1.35 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Anxiety/depression randomized period | 1.32 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Visual analogue scale )VAS) run-in period | 80.97 scores on a scale |
| gammaCore®-R | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Visual analogue scale (VAS) randomized period | 82.46 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Visual analogue scale )VAS) run-in period | 80.3 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Mobility run-in period | 1.10 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Pain/discomfort run-in period | 1.59 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Mobility randomized period | 1.07 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Anxiety/depression randomized period | 1.41 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Selfcare run-in period | 1 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Pain/discomfort randomized period | 1.48 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Selfcare randomized period | 1.02 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Visual analogue scale (VAS) randomized period | 76.35 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Usual activities run-in period | 1.23 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Anxiety/depression run-in period | 1.4 scores on a scale |
| gammaCore®-R Sham | Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L) | Usual activities randomized period | 1.22 scores on a scale |
Secondary
Mean Change in Number of Headache Days
The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.
Time frame: The last four weeks in the randomization period compared to the four week run-in period.
Population: Randomized population, Intention to Treat (ITT)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| gammaCore®-R | Mean Change in Number of Headache Days | -2.28 Days | Standard Deviation 3.623 |
| gammaCore®-R Sham | Mean Change in Number of Headache Days | -1.72 Days | Standard Deviation 3.732 |
Secondary
Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period
Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded: 0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability
Time frame: 3 months - end of run-in period to end of randomized period
Population: Randomized population, Intention to Treat (ITT) At randomisation (visit 2) subject numbers are 165 gammaCore-R and 167 gammaCore-R Sham.~At visit 6 the numbers are lower due to early subject discontinuation: 141 gammaCore-R and 132 gammaCore-R Sham
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade I | 11 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade II | 15 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade III | 23 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade IV | 116 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade I | 22 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade II | 19 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade III | 37 participants |
| gammaCore®-R | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade IV | 63 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade IV | 64 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade I | 11 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade I | 24 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade II | 15 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade III | 27 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade III | 32 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 12 (Visit 6) Grade II | 17 participants |
| gammaCore®-R Sham | Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period | Week 0 of Randomized Period (Visit 2) Grade IV | 109 participants |
Secondary
Number of Participants With 50% Responder Rate
The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.
Time frame: The last four weeks in the randomization period compared to the four week run-in period.
Population: Randomized population, Intention to Treat (ITT)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| gammaCore®-R | Number of Participants With 50% Responder Rate | 47 Participants |
| gammaCore®-R Sham | Number of Participants With 50% Responder Rate | 38 Participants |
Secondary
Number of Participants With Adverse Events
Adverse Effects were collected for all subjects for the duration of the study.
Time frame: up to Week 36
Population: Safety population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| gammaCore®-R | Number of Participants With Adverse Events | Serious adverse events | 2 Participants |
| gammaCore®-R | Number of Participants With Adverse Events | Adverse events (non-serious) | 74 Participants |
| gammaCore®-R Sham | Number of Participants With Adverse Events | Adverse events (non-serious) | 91 Participants |
| gammaCore®-R Sham | Number of Participants With Adverse Events | Serious adverse events | 1 Participants |
| Not Randomized | Number of Participants With Adverse Events | Serious adverse events | 0 Participants |
| Not Randomized | Number of Participants With Adverse Events | Adverse events (non-serious) | 13 Participants |
| Open Label | Number of Participants With Adverse Events | Serious adverse events | 2 Participants |
| Open Label | Number of Participants With Adverse Events | Adverse events (non-serious) | 118 Participants |